Discover the Next IDE Inhibitor with the Newly Launched SensoLyte® IDE Activity Assay

AnaSpec Launches Industry’s First FRET-based Assay for Measurement of Insulin Degrading Enzyme (IDE) Activity for inhibitor high throughput screening- the SensoLyte® 520 IDE Activity Assay Kit
 
 
IDE-AssayTA_Final3
IDE-AssayTA_Final3
 
Spread the Word
Listed Under

Tags:
Ide
FRET-based assay
fluorimetric assay for IDE
Insulin Degrading Enzyme Assay
high throughput screening HTS

Industry:
Biotech

Location:
Fremont - California - US

Subject:
Products

FREMONT, Calif. - June 10, 2014 - PRLog -- Discover your next Insulin Degrading Enzyme (IDE) inhibitor by using the newly launched SensoLyte® 520 IDE activity assay from AnaSpec. This is the first FRET-based (Ex/Em=490/520 nm) IDE assay that is commercially available and can be used for high-throughput screening (HTS) of IDE inhibitor lead compounds. The highly sensitive substrate used in the assay can detect as low as 0.8 ng/ml active IDE and has minimal cross reaction with Neprilysin, TACE, b-Secretase, ADAM10 and BACE2.

Insulin degrading enzyme (IDE), an extremely conserved Zn2+ metalloendopeptidase, belongs to the M16A metallopeptidase family (1-3). IDE is expressed in almost all tissues and distributed in the cytosol. It degrades various substrates such as insulin, IGF-II, TGF-α, glucagon, amylin, calcitonin, β-amyloid and amyloid precursor protein (APP) (4-6). Growing evidence has indicated that IDE may be involved in the pathogenesis of Alzheimer's disease and diabetes mellitus type 2 (2, 7, 8).

For more information, please visit: https://www.anaspec.com/products/promotions.asp?id=125&am...

References
1. Fernández-Gamba, A. et al. Curr Pharm Des 15, 3644 (2009).
2. McCord, LA. et al. Proc Natl Acad Sci USA 110, 13827 (2013).
3. de Tullio, MB. et al. Prion 2, 51 (2008).
4. Edbauer, D. et al. J Biol Chem 277, 13389 (2002).
5. Morelli, L. et al. Biochem Biophys Res Commun 332, 808 (2005).
6. Kurochkin, IV. Trends Biochem Sci 26, 421 (2001).
7. Delledonne, A. et al. Mol Neurodegener 4, 39 (2009).
8. Zhao, J. et al. Mol Neurodegener 4, 4 (2009).

AnaSpec, EGT Group

AnaSpec, EGT Group is a leading provider of integrated proteomics and genomics solutionsTM for worldwide life science research. AnaSpec offers expertise in peptides, detection reagents, antibodies, assay kits, amino acids, oligonucleotides, and Takyon™ qPCR MasterMixes. AnaSpec carries a broad product line of biochemicals and reagents for basic research, high-throughput screening (HTS) and drug discovery.  AnaSpec also provides premier custom services including peptide synthesis, antibody production, assay development, fluorescent dyes, and oligonucleotide synthesis.  AnaSpec is certified to ISO 9001:2008.

For more information visit: www.anaspec.com

Contact
Cecilia Po
***@anaspec.com
End
Source:AnaSpec
Email:***@anaspec.com Email Verified
Tags:Ide, FRET-based assay, fluorimetric assay for IDE, Insulin Degrading Enzyme Assay, high throughput screening HTS
Industry:Biotech
Location:Fremont - California - United States
Subject:Products
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
AnaSpec Inc. PRs
Trending News
Top Daily News
Top Weekly News



Like PRLog?
9K2K1K
Click to Share